**Supplementary Material**

Supplemental table 1. Whole blood generation profile of multiple myeloma patients and controls

|                  | All patients and controls | Patients and controls on anticoagulants excluded |
|------------------|---------------------------|-------------------------------------------------|
|                  | Patients (N = 21)         | Controls (N = 21)                               | Patients (N = 17) | Controls (N = 19) | p-value |
| Lag time (min)   |                           |                                                 |                   |                   |         |
| 0 pM TF          | 24 (20-33)                | 18 (16-22)                                      | 21 (19 - 28)      | 18 (16 - 21)      | 0.011   |
| 1 pM TF          | 5 (4-8)                   | 4 (3-5)                                         | 5 (4 - 7)         | 4 (3 - 5)         | 0.001   |
| TTP (min)        |                           |                                                 |                   |                   |         |
| 0 pM TF          | 33 (25-42)                | 24 (21-28)                                      | 25 (19 - 28)      | 21 (16 - 24)      | 0.008   |
| 1 pM TF          | 14 (11-19)                | 9 (8-10)                                        | 12 (10 - 16)      | 9 (7 - 10)        | <0.001  |
| Peak (nmol/L)    |                           |                                                 |                   |                   |         |
| 0 pM TF          | 233 (121-269)             | 199 (160-278)                                  | 257 (142 - 277)   | 209 (163 - 282)   | 0.918   |
| 1 pM TF          | 197 (128-264)             | 211 (168-266)                                  | 213 (171 - 277)   | 218 (188 - 269)   | 0.77    |
| ETPp (nmol * min/L) |                     |                                                 |                   |                   |         |
| 0 pM TF          | 754 (558-854)             | 577 (492-725)                                  | 775 (642 - 917)   | 578 (500 - 718)   | 0.002   |
| 1 pM TF          | 835 (670-1002)            | 600 (481-732)                                  | 889 (696 - 1012)  | 621 (521 - 747)   | 0.003   |

Median and Interquartile ranges (25%-75%) are indicated. The Mann-Whitney U test was used to compare between groups. The columns on the left show the results for all patients and controls, the columns on the right show the results after exclusion of patients and controls on anticoagulants.

ETPp, endogenous thrombin potential until the peak; TF, tissue factor; TTP, time to peak.
Supplemental table 2. The effect of medication on whole blood thrombin generation in multiple myeloma patients and controls.

| Medication Type                  | Control | Patients without medication | Patients with medication | p-value |
|----------------------------------|---------|-----------------------------|--------------------------|---------|
|                                  |         | Anticoagulants (n)          |                          |         |
| Lag time (min)                   | 21      | 3.7 (3.2 - 4.7)             | 5.0 (4.2 - 7.0)          |         |
| ETPp (nmol*min/L)                | 600 (481 - 732) | 915 (721 - 1012) | 691 (172 - 728) * | 0.0003  |
|                                  | 17      |                            |                          |         |
|                                  | 4       |                            |                          |         |
|                                  |         | Lag time (min)              | 17.0 (10.5 - 49.4) *     | 0.048   |
|                                  |         | ETPp (nmol*min/L)           |                          |         |
| Platelet inhibitor (n)           | 21      | 3.7 (3.2 - 4.7)             | 6.0 (4.8 - 16.8)         | 5.1 (4.0 - 7.9) | 0.27   |
| Lag time (min)                   | 600 (481 - 732) | 765 (642 - 923) | 968 (738 - 1022) | 0.25   |
| ETPp (nmol*min/L)                | 10      |                            |                          |         |
|                                  | 11      |                            |                          |         |
| Immunomodulatory drugs (n)       | 21      | 3.7 (3.2 - 4.7)             | 5.0 (4.6 - 8.2)          | 6.7 (4.1 - 8.1) | 0.54   |
| Lag time (min)                   | 600 (481 - 732) | 889 (789 - 961) | 777 (642 - 1054) | 0.93   |
| ETPp (nmol*min/L)                | 7       |                            |                          |         |
| Corticosteroids (n)              | 21      | 3.7 (3.2 - 4.7)             | 4.5 (3.9 - 9.4)          | 7.0 (5.0 - 8.2) | 0.13   |
| Lag time (min)                   | 600 (481 - 732) | 743 (634 - 974) | 961 (738 - 1002) | 0.28   |
| ETPp (nmol*min/L)                | 10      |                            |                          |         |
| Proteasome inhibitor (n)         | 21      | 3.7 (3.2 - 4.7)             | 6.7 (4.4 - 8.4)          | 5.0 (4.2 - 6.5) | 0.43   |
| Lag time (min)                   | 600 (481 - 732) | 764 (619 - 992) | 968 (902 - 1118) | 0.05   |
| ETPp (nmol*min/L)                | 16      |                            |                          |         |
|                                  | 5       |                            |                          |         |

Thrombin generation was stimulated with 1 pM TF in whole blood of MM patients and controls. The effect of medication on the lag time and endogenous thrombin potential until the peak (ETPp) are shown in the table. Median and Interquartile ranges (25%-75%) are indicated. The difference in WB-TG parameters between patients on the specified medication were compared with those who did not use this specific medication (Mann-Whitney U statistical test) * Patients that used anticoagulants had a prolonged lag time and reduced ETPp compared to patients that did not take anticoagulants. None of the other tested treatments reached statistical significance between users and non-users.